Clinical Trials Logo

Clinical Trial Summary

This study is a single arm phase ll trial including 52 patients with T2N2-3M0#T3-4N0-3M0 (III-V) head and neck squamous cell carcinoma(HNSCC) eligible forresection, who receive Cetuximab+ Zimberelimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperative administration of Cetuximab+ Zimberelimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma(HNSCC) who are about to undergo surgery.


Clinical Trial Description

In this study, eligible subject will be enrolled into study arm to accept study treatment objective response rate will be the primary outcome measures. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06107114
Study type Interventional
Source Sun Yat-sen University
Contact Xuekui Liu
Phone 08613609713406
Email Liuxk@sysucc.org.cn
Status Not yet recruiting
Phase Phase 2
Start date December 1, 2023
Completion date December 1, 2024